Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
September 29 2021 - 6:15PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that it will host a Key Opinion Leader
(KOL) call on its 12-week Phase 1 clinical trial of pemvidutide
(proposed INN, formerly known as ALT-801) in overweight and obese
subjects on Thursday, September 30, 2021 at 9:00 am EST.
The call will feature a discussion with Stephen
A. Harrison, MD (Pinnacle Clinical Research), a leading expert in
the field of non-alcoholic steatohepatitis (NASH) and liver
diseases, on the safety profile and weight loss data generated from
Altimmune’s Phase 1 clinical trial. Dr. Harrison will be available
to answer questions at the conclusion of the
call.
Stephen A. Harrison, MD earned his medical
degree from the University of Mississippi School of Medicine. He
completed his internal medicine residency and gastroenterology
fellowship at Brooke Army Medical Center and a 4th year advanced
liver disease fellowship at Saint Louis University. He is board
certified in both Internal Medicine and Gastroenterology. Dr.
Harrison served as a Professor of Medicine at the Uniformed
Services University of the Health Sciences and is currently a
Visiting Professor of Hepatology at the Radcliffe Department of
Medicine, University of Oxford. He is a past Associate Editor for
Hepatology and Alimentary Pharmacology and Therapeutics. He is a
peer-reviewer for over 20 medical journals and internationally
known for studies in hepatitis C and non-alcoholic fatty liver
disease with over 200 peer reviewed publications in these fields.
Dr. Harrison most recently served as a Colonel in the United States
Army. Retiring in 2016, he concluded 20 years of dedicated service
to his country. During his army tenure, he served as the Director
of Graduate Medical Education at Brooke Army Medical Center,
Associate Dean for the San Antonio Uniformed Services Health
Education Consortium and Gastroenterology Consultant to the Army
Surgeon General. Dr. Harrison currently serves as the Medical
Director for Pinnacle Clinical Research and the President of Summit
Clinical Research.
Conference Call Information:
Date: |
|
Thursday, September 30 |
Time: |
|
9:00 am Eastern Time |
Domestic Dial-in: |
|
(844) 615-6509 |
International Dial-in: |
|
(918) 922-3148 |
Conference ID: |
|
4595573 |
Webcast: |
|
https://edge.media-server.com/mmc/p/igi7kfsz |
|
|
|
Following the conclusion of the call, the webcast will be
available for replay on the Investor Relations page of the
Company’s website at www.altimmune.com. The company has used, and
intends to continue to use, the IR portion of its website as a
means of disclosing material non-public information and for
complying with disclosure obligations under Regulation FD.
About PemvidutidePemvidutide
(proposed INN, formerly known as ALT-801) is a novel,
investigational, peptide-based dual GLP-1/glucagon receptor agonist
that is designed to treat obesity and non-alcoholic steatohepatitis
(NASH). Altimmune believes the treatment of obesity is the
cornerstone of treating NASH and its co-morbidities and views the
treatment of obesity and NASH as significant unmet medical needs
that can be addressed through significant weight loss.
In a 12-week Phase 1 study in Australia,
subjects receiving pemvidutide achieved mean weight losses of 4.9%,
10.3%, and 9.0% at 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively,
with the placebo group experiencing a mean weight loss of 1.6%.
Weight loss occurred rapidly and consistently over 12-weeks. Side
effects were mild to moderate, with no serious or severe
treatment-emergent adverse events. Importantly, no discontinuations
due to adverse events were reported. For more information on the
trial, refer to the September 28, 2021 press release here.
About AltimmuneAltimmune is a
clinical stage biopharmaceutical company focused on developing
treatments for obesity and liver diseases. Our pipeline includes
next generation peptide therapeutics for obesity, NASH
(pemvidutide), and chronic hepatitis B (HepTcell™). For more
information on Altimmune, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Investor and Media Contact:Will BrownChief
Financial OfficerPhone: 240-654-1450wbrown@altimmune.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2023 to Apr 2024